Evidence map›Paper›PMID 31236902›Full record

ReviewHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2019

Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.

Rita Del Pinto, Davide Grassi, Giuliana Properzi, Giovambattista Desideri, Claudio Ferri

Abstract readReview
PubMed Publisher
In one paragraph

Review in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020
    Review
  11. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rita Del PintoDepartment of Life, Health and Environmental Sciences, San Salvatore Hospital, University of L'Aquila, Building Delta 6, L'Aquila, Italy. ritadelpinto@gmail.com.ORCID http://orcid.org/0000-0003-4058-0655
Davide GrassiDepartment of Life, Health and Environmental Sciences, San Salvatore Hospital, University of L'Aquila, Building Delta 6, L'Aquila, Italy.
Giuliana ProperziDepartment of Life, Health and Environmental Sciences, San Salvatore Hospital, University of L'Aquila, Building Delta 6, L'Aquila, Italy.
Giovambattista DesideriDepartment of Life, Health and Environmental Sciences, San Salvatore Hospital, University of L'Aquila, Building Delta 6, L'Aquila, Italy.
Claudio FerriDepartment of Life, Health and Environmental Sciences, San Salvatore Hospital, University of L'Aquila, Building Delta 6, L'Aquila, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9)-related discoveries of the turn of the century have translated into substantial novelty in dyslipidemia treatment in the last 5 years. With chronic preventable atherosclerotic cardiovascular diseases (ASCVD) representing an epidemic of morbidity and mortality worldwide, low-density lipoprotein cholesterol (LDL-c) reduction represents a public health priority. By overcoming two major statin-related issues, namely intolerance and ineffectiveness, PCSK9 inhibitors have offered a safe and effective option in selected clinical settings where LDL-c reduction is required. Herein, we recapitulate recent findings, clinical applications, and ASCVD prevention potential of PCSK9 inhibition, with focus on anti-PCSK9 monoclonal antibodies, evolocumab and alirocumab.

Indexed as

PCSK9 InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtherosclerosisBiomarkersCholesterol, LDLDyslipidemiasHumansPractice Guidelines as TopicProprotein Convertase 9Risk FactorsSerine Proteinase InhibitorsTreatment OutcomealirocumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsBiomarkersCholesterol, LDLevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine Proteinase InhibitorsAntibodies, monoclonalAnticholesteremic agentsAtherosclerotic plaqueCardiovascular diseasesCholesterol, LDLProprotein convertases, subtilisin–kexin family

Identifiers

PMID31236902

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.